Table 2.
Characteristics of patients undergoing first-line treatment with successful and failed eradication, n (%)
| Characteristic |
Total, n = 250 |
VA success, n = 239 |
VA failure, n = 11 |
P value |
| Age in years | 65.3 ± 4.4 | 65.4 ± 4.4 | 63.4 ± 4.1 | 0.1500 |
| Range | 60-82 | 60-82 | 60-72 | |
| Sex as M/F | 106/144 | 103/136 | 3/8 | 0.3600 |
| Body weight in kg | 65.5 ± 11.3 | 65.4 ± 11.1 | 67.4 ± 14.4 | 0.6400 |
| BMI in kg/m2 | 24.0 ± 3.4 | 23.99 ± 11.1 | 24.8 ± 3.7 | 0.5000 |
| Cigarette smoking | 31 (12.4) | 30 (12.5) | 1 (9.1) | 1.0000 |
| Alcohol drinking | 35 (14.0) | 34 (14.2) | 1 (9.1) | 1.0000 |
| Family history of gastric cancer | 15 (6.0) | 14 (5.9) | 1 (9.1) | 0.5000 |
| Endoscopy diagnosis | ||||
| Gastritis | 193 (77.2) | 183 (76.6) | 10 (90.9) | 0.7000 |
| CSG | 108 (43.2) | 105 (43.9) | 3 (27.3) | 0.3500 |
| CAG | 85 (34.0) | 78 (32.6) | 7 (63.6) | 0.0490a |
| Peptic ulcer | 51 (20.4) | 50 (20.9) | 1 (9.1) | 0.4700 |
| Gastric ulcer | 14 (5.6) | 14 (5.9) | 0 | 1.0000 |
| Duodenal ulcer | 27 (10.8) | 26 (10.9) | 1 (9.1) | 1.0000 |
| Complex (gastric and duodenal) ulcer | 10 (4.0) | 10 (4.2) | 0 | 1.0000 |
| Gastric cancer | 1 (0.4) | 1 (0.4) | 0 | 1.0000 |
| MALToma | 3 (1.2) | 3 (1.3) | 0 | 1.0000 |
| Gastric hyperplastic polyp | 2 (0.8) | 2 (0.8) | 0 | 1.0000 |
| Combined diseases | 1.8 ± 1.4 | 1.8 ± 1.4 | 1.5 ± 1.4 | 0.4300 |
| 0 | 53 (21.2) | 50 (20.9) | 3 (27.3) | 0.7100 |
| 1 | 61 (24.4) | 57 (23.8) | 4 (36.4) | 0.4700 |
| 2 | 64 (25.6) | 63 (26.4) | 1 (9.1) | 0.3000 |
| ≥ 3 | 72 (28.8) | 69 (28.9) | 3 (27.3) | 1.0000 |
| Combined medicine | 1.3 ± 1.6 | 1.4 ± 1.6 | 0.7 ± 1.2 | 0.1100 |
| 0 | 99 (39.6) | 92 (38.5) | 7 (63.6) | 0.1200 |
| 1 | 59 (23.6) | 57 (23.8) | 2 (18.2) | 1.0000 |
| 2 | 40 (16.0) | 40 (16.7) | 0 | 0.2200 |
| ≥ 3 | 52 (20.8) | 50 (20.9) | 2 (18.2) | 0.1300 |
| Comorbidity | ||||
| Hypertension | 89 (35.6) | 86 (36.0) | 3 (27.3) | 0.7500 |
| Diabetes mellitus | 45 (18.0) | 44 (18.4) | 1 (9.1) | 0.6900 |
| Hyperlipidemia | 88 (35.2) | 85 (35.6) | 3 (27.3) | 0.7500 |
| Heart disease | 32 (12.8) | 32 (13.4) | 0 | 0.3800 |
| Lung disease | 10 (4.0) | 10 (4.2) | 0 | 1.0000 |
| Liver disease | 28 (11.2) | 26 (10.9) | 2 (18.2) | 0.3500 |
| Renal disease | 13 (5.2) | 12 (5.0) | 1 (9.1) | 0.4500 |
| Cerebrovascular disease | 10 (4.0) | 10 (4.2) | 0 | 1.0000 |
| Autoimmune disease | 24 (9.6) | 22 (9.2) | 2 (18.2) | 0.2900 |
| Hypersensitivity disease | 4 (1.6) | 4 (1.7) | 0 | 1.0000 |
| Malignant tumor | 25 (10.0) | 22 (9.2) | 3 (27.3) | 0.0900 |
| Compliance | 246 (98.4) | 238 (99.6) | 8 (72.7) | 0.0003c |
| Adverse events | 23 (9.2); 95%CI: 6.2%-13.4% | 21 (8.8) | 2 (18.2) | 0.2900 |
| Eradication rate | 95.6% (239/250); 95%CI: 93.0%-98.1% |
P < 0.05.
P < 0.001.
Data are mean ± SD unless otherwise indicated. Cigarette smoking was defined by consumption of > 5 cigarettes a day or > 1 cigarette pack/week consumed in the past 6 months. A family history of gastric cancer was defined as a gastric cancer diagnosis in a first-degree relative (such as a parent, sibling, or child). Alcohol drinking was defined by > 50 g of alcohol/day consumed in the past 6 months. Compliance was defined by > 80% of tablets taken as instructed. BMI: Body mass index; CSG: Chronic superficial gastritis; CAG: Chronic astrophic gastritis; F: Female; M: Male; MALToma: Mucosa-associated lymphoid tissue lymphoma; VA: Vonaprazan-amoxicillin.